Top trends in Cross-Border Biotech BD - China Innovation On Focus

KOL: Leon Tang, PhD Founder of InScienceWeTrust BioAdvisory & InSciecneWeTrust Community

Moderators:
Li Watsek, Senior Analyst, Cantor Fitzgerald
Eric Schmidt, PhD, Senior Analyst, Cantor Fitzgerald

Discussion Topics:
Chinese biotech innovation has been a key theme this year. In this 40-min
call, we will dive into the following topics:

00:00 Self introduction of Leon Tang
04:00 The top three trends in 2024.
08:00 Big pharma's pending patent cliff, poor capital markets in China, and a shift in mindset are the driving forces behind the uptick in cross-border BD activities.
11:40 The impacts of distressed China capital market and the extreme pricing control.
14:55 Why China out-licensing boom is not a one-time phenomenon but will continue.
17:28 How is the valuation of deals determined regarding China-outbound deals? And how do they compare with deals from US/EU companies? Hint PD-1/VEGF deals
20:20 What types of assets are hot when VC funds look for assets in China?
22:55 Why we have not seen many radiopharmaceutical deals out of China yet?
24:30 Why is the newco model so popular? Which challenges does the model try to address?
Hint, Hengrui/Kailera newco opens Chinese companies' imagination.
27:19 What are the typical DD process to source China innovation?
29:18 Which Western companies are experienced in licensing China innovation? How can new players enter this space?
30:35 How can Western VC funds and biotech companies efficiently source China innovation? Hint: contact us at ISWT BioAdvisory :p
34:07 How can Western partners find the high-quality programs in China? Hint: there is difference between the DD requirement between big pharmas and VC funds/small biotechs
37:03 Is China innovation a friend or foe to the US biotechs?
39:40 How should we think about the threat from BIOSECURE Act and geopolitical tensions on the US/China deal-making boom? Hint: European companies are not subject to the US regulations regarding sourcing China innovation.
41:55 What do you think the future of West/China BD&L trend in 2025 and beyond?

Please join the discussion on our company LinkedIn page here:   / urn:li:activity:7266888068190638080